Democrats’ midterm wins could reshape healthcare policy, with a new Democratic Congress positioned to pursue bipartisan limits on prior authorization and tougher scrutiny of pharmacy benefit managers — moves clinicians say could reduce treatment delays and drug-cost friction for patients. Even with President Donald Trump able to veto broader reforms, health policy experts say Congress may still advance narrower affordability measures while using oversight powers to challenge administration health actions.

The Move

• Democrats’ control of the House and Senate gives them leverage to push healthcare legislation and investigations, including proposals to curb prior authorization and examine PBM pricing and rebate practices.

• Experts quoted in the article say prior auth reform may be one of the clearest areas for bipartisan action, especially as the Trump administration has already taken steps to crack down on the practice.

• Lawmakers could also pair those efforts with broader affordability pushes on prescription drugs and hospital costs, though any major bill would still need Trump’s signature.

Why it Matters for Care

• For clinicians, prior authorization is a direct practice issue: it can delay tests, medications, and procedures that physicians consider medically necessary.

• Any federal limits on prior auth could ease administrative burden, speed treatment starts, and reduce disruptions in continuity of care.

• PBM reforms could also affect formulary access, patient out-of-pocket costs, and prescribing decisions at the bedside.

Between the Lines

• Democrats are more likely to focus on targeted, politically saleable healthcare fixes than sweeping reforms, given Trump’s veto threat.

• That creates an opening for measures framed around affordability, insurer practices, and market middlemen rather than large coverage expansions alone.

• Oversight is also part of the strategy: hearings and subpoenas aimed at Health Secretary Robert F. Kennedy Jr. and other officials could slow or spotlight administration policies while building a 2028 campaign record.

What to Watch

• Whether congressional leaders introduce bipartisan prior auth or PBM bills early in the next session.

• How Trump responds to narrower healthcare cost proposals, especially if they align with his stated interest in lowering drug prices.

• Parallel fights over ACA subsidy restoration, Medicaid work requirements, and investigations into vaccine policy changes led by Kennedy and federal health agencies.

Source: NBC News Health